Cardiovascular involvement among collegiate athletes following COVID-19 infection

Christle C. Guevarra1*, Nicholas Murray2, Daniel Cipriani3, Kevin Maillard1, Amber Char4, Kyle Coffman5, Cameron Davis1, Frank Truong1, Alfred Danielian6, Glenn Barnes1, Wade Gaal1

1Department of Family and Community Medicine, University of Nevada Las Vegas, Las Vegas, NV, United States, 2School of Community Health Sciences, University of Nevada Reno, Reno, NV, United States, 3Center for Graduate Studies, West Coast University, Los Angeles, CA, United States, 4Crozer Health Family Medicine Residency, Springfield, PA, United States, 5Kirk Kerkorian School of Medicine at University of Nevada Las Vegas, Las Vegas, NV, United States, 6Director of Sports Cardiology and Echocardiography, Las Vegas Heart Associates, Las Vegas, NV, United States

ABSTRACT

Background: Recent studies suggest that the prevalence of cardiac involvement in young competitive athletes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection appears to be low.

Aim: This study aimed to determine the prevalence of cardiovascular involvement in young competitive athletes.

Methods: In this single-center retrospective cohort study from one Division I university; we assessed the prevalence of cardiovascular involvement among collegiate athletes who tested positive for SARS-CoV-2 by polymerase chain reaction testing. Data were collected from June 25, 2020, to May 15, 2021. The primary outcome was the prevalence of cardiac involvement based on a comparison of pre- and post-infection electrocardiogram (ECGs). The secondary outcome was to evaluate for any association between ethnicity and the presence or absence of symptoms.

Results: Among 99 athletes who tested positive for the SARS-CoV-2 virus (mean age 19.9 years [standard deviation 1.7 years]; 31% female), baseline ECG changes suggestive of cardiovascular involvement post-infection were detected in two athletes (2/99; 2%). There was a statistically significant association between ethnicity and the presence or absence of symptoms, $\chi^2 (3, n = 99) = 10.61, P = 0.01$.

Conclusions: The prevalence of cardiovascular involvement among collegiate athletes following SARS-CoV-2 infection in this cohort is low. Afro-American and Caucasian athletes are more likely to experience symptoms following SARS-CoV-2 infection in comparison to Hispanic and Pacific Islander athletes; however, there is no association between ethnicity and symptom severity.

Relevance for Patients: These data add to the growing body of the literature and agree with larger cohorts that the risk of cardiac involvement post-infection appears to be low among elite athletic and semi-professional athletic populations.

1. Introduction

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified on December 31, 2019, and declared a pandemic on March 11, 2020, by the World Health Organization. To date, over 173 million people have been infected with the SARS-CoV-2 virus with over 3.7 million deaths [1]. While these data are staggering, it is important to understand the potential health implications of this virus across infected individuals.
A significant fraction of hospitalized and critically ill patients with coronavirus disease has exhibited multiple cardiovascular complications, including acute myocardial injury, heart failure, myocarditis, arrhythmias, venous thromboembolism, and cardiogenic shock [2-4]. While the majority of hospitalized patients have prior existing conditions [5,6] which could lead to or be a precursor of cardiovascular complications, it is unclear what cardiac risk exists for asymptomatic or mildly symptomatic cases. This is important given that the majority of young adults or physically active individuals, specifically NCAA Division I athletes, have little to no symptoms of COVID-19. Viral myocarditis is a known cause of sudden cardiac death in athletes and physically active individuals [7-10]. The evolving understanding of the risk of cardiovascular sequelae in athletes following SARS-CoV-2 infection is currently being reflected in the ongoing updating of return-to-play guidelines for athletes and active individuals [11-19].

Abnormal cardiac magnetic resonance (CMR) imaging in middle-aged, ambulatory adults recovering from COVID-19 has been reported to be as high as 78%, sparking concern about COVID-19 myocarditis in athletes [20]. One of the earliest cohort studies investigating professional soccer players noted no cardiac involvement after undergoing return-to-play (RTP) cardiac testing [21]. Further studies examining professional athletes undergoing RTP cardiac testing reported a low prevalence of cardiac involvement (0.6%) [22]. Single-center observational cohort studies of collegiate athletes reported varying degrees of cardiac involvement following RTP cardiac testing (1.4–56%); however, the prevalence of myocarditis is much less so (0–15%) [23-26]. The largest to date multicenter observational cohort study involving over 3000 collegiate athletes with SARS-CoV-2 infection undergoing RTP cardiac testing reported a low prevalence of cardiac involvement (0.5–3%) [27]. The most recent observational cohort study of collegiate athletes reported a low prevalence of abnormal cardiac testing (3.6%), with no evidence of myocarditis after further workup by CMR [28]. These findings have provided a critical foundation for understanding the risk of myocarditis among athletes but more data are needed which include pre-infection health status. These important data can aid clinical decisions regarding RTP and may rule out the possibility of expensive time-intensive procedures.

The purpose of this retrospective cohort study was to evaluate the prevalence of cardiac involvement in collegiate athletes recovering from COVID-19 infection based on a comparison of pre- and post-infection electrocardiogram (ECG). It was hypothesized that those with positive pre-infection cardiac involvement would demonstrate exaggerated or worse outcomes following a positive COVID-19 diagnosis.

2. Materials and Methods

De-identified retrospective data were collected from June 20, 2020, to May 15, 2021, through chart review from a single NCAA Division I school. This study was granted exempt status by the University of Nevada Las Vegas Institutional Review Board (Protocol #1632049-4). Data will be made available on reasonable request.

All NCAA student-athletes at the University of Nevada Las Vegas who had an ECG done as part of their pre-participation evaluation and tested positive for SARS-CoV-2 by polymerase chain reaction (PCR) were eligible to participate. Written informed consent was obtained for each participant. Athletes were excluded from the study if they were unable to be contacted to provide written informed consent, declined informed consent, had a positive SARS-CoV-2 test that was not medically documented, did not have a pre-participation ECG on file, only had a clinical assessment with no additional cardiac testing, or have yet to complete their cardiac evaluation by the end of the collection date. Student-athletes or the public were not involved in the design, conduct, reporting, or dissemination plans of this cohort study.

Athletes were required to complete a mandatory daily symptom screener and any positive symptoms were flagged and recorded by an athletic trainer. Symptom severity was categorized based on the reported symptoms from the initial infection or during their mandatory isolation period as initially proposed for collegiate athletes [29]. Symptoms were categorized as follows: Asymptomatic, mild, and moderate. Mild symptoms were defined as cough, fatigue, headache, anosmia, ageusia, rhinorrhea, sore throat, nasopharyngeal congestion, nausea, vomiting, or diarrhea. Moderate symptoms included cardiopulmonary symptoms and were defined as fever, chills, myalgias, chest pain, shortness of breath, palpitations, or exercise intolerance. If an athlete had symptoms in multiple categories, they were assigned to the most severe category. Post-infection evaluations included both a clinical assessment and a 12-lead ECG no sooner than 10 days after the positive test. All ECGs were interpreted using the International Criteria for ECG Interpretation in Athletes [30]. Each ECG post-infection was compared to the athlete’s pre-participation ECG. Further cardiac testing was determined by the severity of symptoms and included a cardiac troponin T assay (Quest Diagnostics; cutoff range 0.01 ng/mL), TTE, CMR, and/or clinical assessment by a sports cardiologist [12]. Athletes with a normal clinical evaluation and negative cardiac testing were cleared to start a graduated return to play program as previously described [14].

Every athlete had a 12-lead ECG as part of their pre-participation evaluation. Each ECG was interpreted using the International Criteria for ECG Interpretation in Athletes [30]. Any pre-season ECG abnormalities were documented and had follow-up assessments through a sports cardiologist which included exertional testing to rule out any potential complications from sports participation.

Patient demographics, ECG changes, and SARS-CoV-2 symptom categories were described using basic descriptive methods. Associations between ethnic groups and symptom categories were calculated using the Chi-square test of independence. In addition, Chi-square tests were used to determine any associations between type of sport participation and the reporting of symptoms and severity of symptoms. Statistical analyses were performed using JASP (Version 0.14.1, University of Amsterdam, Amsterdam, Netherlands).

3. Results

Of the 120 athletes enrolled during the study period, 99 met the study inclusion criteria. Baseline characteristics for the cohort are
shown in Table 1. Athletes were young adults (mean age 19.9 years; standard deviation 1.7 years). The median time between COVID-19 diagnosis and ECG test was 15 days (interquartile range 11 and 18 days). Athletes from ten different sports were represented: Football, soccer, baseball, softball, basketball, volleyball, track and field, cross country, swimming and diving, and tennis. Three athletes had abnormal pre-season ECGs that were referred to cardiology for further evaluation and were cleared to participate in sport. Cardiac return-to-play testing is also described below.

Of all athletes testing positive, there was a significant association between ethnicity and symptom development ($\chi^2 = 11.27, \text{df} = 3, n = 99, P = 0.01$). Individuals of Afro-American and Caucasian ethnicity were more likely to develop symptoms (79% and 74%, respectively) compared with individuals of Hispanic or Pacific Islander ethnicity (33% and 58%, respectively). However, in terms of symptom severity, there was no association between mild or moderate symptom development with ethnicity (Afro-American = 35% moderate, Caucasian = 17% moderate, Hispanic = 25% moderate, and Pacific Islander = 29% moderate) with a $\chi^2 = 2.63$, df = 3, and $P = 0.45$. In addition, there was no significant association between gender and symptom development ($\chi^2 = 0.27$ and $P = 0.61$) nor between gender and symptom severity ($\chi^2 = 0.20$ and $P = 0.66$).

Table 1. Patient characteristics

| Patient characteristics | Total cohort (n=99) |
|-------------------------|--------------------|
| Demographics            |                    |
| Age, mean (standard deviation) | 19.9 (1.7) |
| Male                    | 68                 |
| Female                  | 31                 |
| White                   | 42                 |
| Afro-American           | 33                 |
| Hispanic                | 12                 |
| Pacific Islander        | 12                 |
| Sport                   |                    |
| Football (American)     | 44                 |
| Soccer                  | 16                 |
| Baseball                | 4                  |
| Basketball              | 5                  |
| Softball                | 2                  |
| Tennis                  | 2                  |
| Volleyball              | 11                 |
| Track & Field/Cross Country | 1            |
| Swim & Dive             | 14                 |
| Symptom Categories      |                    |
| Asymptomatic            | 29                 |
| Mild                    | 51                 |
| Moderate                | 17                 |
| Symptomatic – unknown severity | 2     |
| Cardiac Return-to-Play Testing |            |
| Electrocardiogram       | 99                 |
| Transthoracic echocardiography | 46  |
| Troponin T              | 49                 |
| Cardiac MRI             | 2                  |

Finally, there was no significant association between type of sport and the presence of symptoms ($\chi^2 = 11.91, \text{df} = 10, and P = 0.28$), nor between the type of sport and the severity level of any symptoms ($\chi^2 = 8.41, \text{df} = 9, and P = 0.49$). Sport type was not associated with symptom reporting. Tables 1 and 2 provide the specific findings for these athletes relative to symptom rate and severity of symptoms.

Abnormal post-infection ECG changes were detected in two athletes (2% of the sample) and the specifics of these findings are described in Table 3. Both of these athletes had normal troponin T levels and no abnormal findings on CMR with late gadolinium enhancement. One of these athletes (#1) had abnormal ECG findings before the beginning of the athletic season; however, the exercise treadmill stress testing revealed frequent premature ventricular complexes that resolved with exercise. Accounting for the abnormal pre-season ECG, the rate of abnormal ECG values post-infection was 1% while no other markers of myocarditis were observed in the present study. The remainder of the cardiac return-to-play testing in this cohort was normal.

4. Discussion

The purpose of this study was to evaluate the prevalence of cardiac involvement in collegiate athletes recovering from COVID-19 infection based on a comparison of pre- and post-infection ECGs. The hypothesis was not met as the three athletes who had an abnormal pre-participation ECG did not have a positive diagnosis of cardiomyopathy. The main implications of this study are: (1) No clinically diagnosed cases of myocarditis were detected within this cohort of athletes; (2) rate of cardiac involvement was extremely low (1%) even among mild-to-moderate cases of COVID-19, and (3) Afro-American and Caucasian ethnicity were more likely to develop symptoms following a positive diagnosis of COVID-19. This is the first study, to the authors’ best knowledge, that used a pre- and post-design in the measurement of cardiac involvement among NCAA athletes and a larger cohort is needed to confirm these findings.

These data add to the growing body of the literature and agree with larger cohorts that the risk of cardiac involvement post-infection is rare (<1–1%) among elite athletic populations [21-28] and 3.3% among semi-professional athletes [31]. These rates are lower than the suggested 78% in ambulatory adults [20], an average incidence of 22 of 100,000 patients according to the Global Burden of Disease Study [32] and following influenza infection (1–10%) [33] among general populations. The potential disease burden of myocarditis appears to be dependent on the health status of the individual while

Table 2. Symptom severity

| Asymptomatic | Mild | Moderate | Symptomatic - unknown severity |
|--------------|------|---------|------------------------------|
| Afro-American (n=33) | 7    | 17      | 9                            |
| Caucasian (n=42) | 9    | 26      | 5                            |
| Hispanic (n=12)  | 8    | 3       | 1                            |
| Pacific Islander (n=12) | 5    | 5       | 2                            |
the risk appears to be lower if you are considered an elite athlete. This is not surprising given the evidence that intense exercise aids in reducing overall cardiac disease risk [34] and enhances immune function [35]. Further research is needed within adolescent athletes and specifically within specific sport types.

The lack of a single consistent site for PCR testing may have inflated the overall positive diagnosis of COVID-19 as each testing facility may have varying cycle thresholds. However, it can be assumed that each PCR testing site followed the CDC’s recommendations for cycle thresholds. Furthermore, the total amount of asymptomatic cases was similar to other studies within NCAA athletes.

Acknowledgments

The authors would like to thank the dedicated support of the Sports Medicine Staff at the University of Nevada Las Vegas: Eric Avila, MS; Kristie Lin, ATC; Katie Draschner, M.Ed; Bryan Lindl, MS; Cole Greenspan, MS; Austin Burns, MS; Krysta Fryer, ATC; and Sonja Kriewald, M.Ed. Contributors were not compensated for their work.

Conflict of Interest

Dr. Murray received payments during the project from NIH grant: P20GM103650. All other authors declare no conflict of interest.

References

[1] World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Organization; 2021. Available from: https://covid19.who.int. Last accessed on 2021 May 21.

[2] Driggin E, Mahavan ME, Bikdeli B, Chuich T, Laracy J, Meissner K, et al. Cardiac Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol 2020;75:2352-71.

[3] Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and Cardiovascular Disease. Circulation 2020;141:1648-55.

[4] Lindner D, Fitzek A, Bräuninger H, Aleshcheva G, Edler C, Meissner K, et al. Association of Cardiac Infection with SARS-CoV-2 in Confirmed COVID-19 Autopsy Cases. JAMA Cardiol 2020;5:1281-5.

[5] Centers for Disease Control and Prevention. COVID-19: COVID-19-Associated Hospitalization Surveillance Network. Atlanta, Georgia, United States: Centers for Disease Control and Prevention; 2021. Available from: https://gis.cdc.gov/grasp/covidnet/COVID19_5.html Last accessed on 2021 Jun 09.

[6] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323:2052-9.

[7] Schmied C, Borjesson M. Sudden Cardiac Death in Athletes. J Intern Med. 2014;275:93-103.

[8] Eckhart RE, Scoville SL, Campbell CL, Shry EA, Stajduhar KC, Potter RN, et al. Sudden Death in Young Adults: A 25-Year Review of Autopsies and Military Recruits. Ann Intern Med 2004;141:829-34.

[9] Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, et al. Incidence, Etiology, and Comparative Frequency of Sudden Cardiac Death in NCAA Athletes: A Decade in Review. Circulation 2015;132:10-9.

[10] Peterson DF, Kucera K, Thomas LC, Maleszewski J, Siebert D, Lopez-Anderson M, et al. Aetiology and Incidence of Sudden Cardiac Arrest and Death in Young Competitive Athletes in the USA: A 4-Year Prospective Study. Br J Sports Med 2021;1:1-9.

[11] Barker-Davies RM, O’Sullivan O, Senaratne KP, Baker P, Cranley M, Dharm-Datta S, et al. The Stanford Hall Consensus Statement for post-COVID-19 Rehabilitation. Br J Sports Med 2020;54:949-59.

[12] Baggish A, Drezner JA, Kim J, Martinez M, Prutkin JM. Resurgence of Sport in the Wake of COVID-19: Cardiac Considerations in Competitive Athletes. Br J Sports Med 2020;54:1130-1.

[13] Phelan D, Kim JH, Chung EH. A Game Plan for the Resumption of Sport and Exercise after Coronavirus Disease 2019 (COVID-19) Infection. JAMA Cardiol 2020;5:1085-6.

[14] Drezner JA, Heinz WM, Asif IM, Batten CG, Fields KB, Neha P. Cardiopulmonary Considerations for High School Student-Athletes during the COVID-19 Pandemic: NFHS-AMSSM Guidance Statement. Sports Health. 2020;12:459-61.

[15] Bhatia RT, Marwaha S, Malhotra A, Iqbal Z, Hughes C, Börjesson M, et al. Exercise in the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Era: A Question and Answer session with the experts Endorsed by the section of Sports Cardiology and Exercise of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol 2020;27:1242-51.

[16] Elliott N, Martin R, Heron N, Elliott J, Grimstead D, Biswas A. Infographic. Graduated Return to Play Guidance Following COVID-19 Infection. Br J Sports Med 2020;54:1174-5.
Cardiorespiratory Considerations for International Criteria for

Brito D, Meester S, Yanamala N, Patel HB, Balcik BJ, Starekova J, Bluemke DA, Bradham WS, Eckhardt LL, Clark DE, Parikh A, Dendy JM, Diamond AB, Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Martinez MW, Tucker AM, Bloom OJ, Green G, Gervasi SF, Pengue L, Damato L, Monti R, Pradella S, Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Guevarra et al. | Journal of Clinical and Translational Research 2022; 8(1): 1-5

National Collegiate Athletic Association. Resocialization of Collegiate Sport: Developing Standards for Practice and Competition. 2nd ed. Indianapolis, Indiana: National Collegiate Athletic Association. Available from: https://ncaaorg.s3.amazonaws.com/ssi/COVID/SSI_ResocializationDevelopingStandardsSecondEdition.pdf Last accessed on 2021 May 26.

Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020;5:1265-73.

Gervasi SF, Pengue L, Damato L, Monti R, Pradella S, Pirronta T, et al. Is extensive cardiopulmonary screening useful in athletes with previous asymptomatic or mild SARS-CoV-2 infection? Br J Sports Med. 2021;55:54-61.

Martinez MW, Tucker AM, Bloom OJ, Green G, DiFiori JP, Solomon G, et al. Prevalence of Inflammatory Heart Disease among Professional Athletes With Prior COVID-19 Infection who Received Systematic Return-to-Play Cardiac Screening. JAMA Cardiol 2021;6:745-52.

Rajpal S, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, et al. Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From Coronavirus Infection. JAMA Cardiol 2021;6:116-8.

Clark DE, Parikh A, Dendy JM, Diamond AB, George-Durrett K, Fish FA, et al. COVId-19 Myocardial Pathology Evaluation in Athletes with Cardiac Magnetic Resonance (COMPETE CMR). Circulation 2021;143:609-12.

Starekova J, Bluemke DA, Bradham WS, Eckhardt LL, Grist TM, Kusmirek JE, et al. Evaluation for Myocarditis in Competitive Student Athletes Recovering From Coronavirus Disease 2019 with Cardiac Magnetic Resonance Imaging. JAMA Cardiol 2021;6:945-50.

Brito D, Meester S, Yanamala N, Patel HB, Balcić BJ, Casaclang-Verzosa G, et al. High Prevalence of Pericardial Involvement in College Student Athletes Recovering from COVID-19. JACC Cardiovasc Imaging 2021;14:541-55.

Moulson N, Petek BJ, Drezner JA, Harmon KG, Kliethermes SA, Patel MR, et al. SARS-CoV-2 Involvement in Young Competitive Athletes. Circulation 2021;144:256-66.

Hendrickson BS, Stephens RE, Chang JV, Amburn JM, Pierotti LL, Johnson JL, et al. Cardiovascular Evaluation after COVID-19 in 137 Collegiate Athletes: Results of an Algorithm-Guided Screening. Circulation 2021;143:1926-8.

American Medical Society for Sports Medicine and the American College of Cardiology. Cardiac Considerations for College Student-Athletes during the COVID-19 Pandemic. American Medical Society for Sports Medicine and the American College of Cardiology; 2020. Available from: https://www.amssem.org/Content/pdf-files/COVID19/NCAA-COVID-19-Algorithm-12-AUG-2020.pdf Latest accessed on 2021 May 27.

Drezner JA, Sharma S, Baggish A, Papadakis M, Wilson MG, Prutkin JM, et al. International Criteria for Electrocardiographic Interpretation in Athletes: Consensus Statement. Br J Sports Med 2017;51:704-31.

Cavigli L, Frascano F, Turchini F, Mochi N, Sarto P, Bianchi S, et al. A Prospective Study on the Consequences of SARS-CoV-2 Infection on the Heart of Young Adult Competitive Athletes: Implications for a Safe Return-to-play. Int J Cardiol 2021;336:130-6.

Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bollinger I, et al. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 301 Acute and Chronic Diseases and Injuries in 188 Countries, 1990-2013: A Systematic Analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743-800.

Ukimura A, Satomi H, Ooi Y, Kanzaki Y. Myocarditis Associated with Influenza A H1N1pdm2009. Influenza Res Treat 2012;2012:351979.

US Department of Health and Human Services. Physical Activity Guidelines for Americans. 2nd ed. Washington, DC: US Department of Health and Human Services. Available from: https://health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2ndEdition.pdf Last accessed on 2021 Jun 09.

Shirvani H, Rostamkhani F, Arabzadeh E, Mohammadi F, Mohammadi F. Potential Role of Nigella sativa Supplementation with Physical Activity in Prophylaxis and Treatment of COVID-19: A Contemporary Review. Sport Sci Health 2021;17:1-6.

Publisher’s note
Whioce Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

DOI: http://dx.doi.org/10.18053/jctres.08.202201.004